In this Issue
- Lykos CEO Provides AdComm Feedback to FDA Commissioner
- Cybin Plans to Fight Functional Unblinding with ‘Firewall’
- Doblin Charts a Future for MAPS • DEA Plots Ketamine Crackdown
- Colorado Closes First Round of Rulemaking for State Psychedelics Program.
- Other Stories, including: MindMed’s Phase 3 program; upcoming FDA-affiliated event on PTSD treatments.
***
Lykos CEO Provides AdComm Feedback to FDA Commissioner
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue